{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Alpha-Synuclein (a-syn), a 140 amino acid protein associated with presynaptic membranes in brain, is a major constituent of Lewy bodies in Parkinson's disease (PD). Three missense mutations (A30P, A53T and E46K) in the a-syn gene are associated with rare autosomal dominant forms of familial PD.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the misfolding and aggregation of alpha-synuclein, leading to Lewy body formation in Parkinson's disease. It is implied that the functional assay can show a difference in binding affinity between wild-type and mutant SNCA, which can affect protein accumulation and aggregation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In the present study, we analysed the ability of cytosolic factors to regulate a-syn binding to synaptic membranes... Our results revealed that ATP and lipids are two of the principal cytosolic components that modulate the a-syn binding.",
          "judgment": "Yes",
          "reasoning": "The assay class (binding assay) is applicable to the disease mechanism, as it directly probes the interaction of alpha-synuclein with membranes, which is relevant to its normal function and pathological aggregation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Figure 1A: Synaptosomes from a-syn-/- mice... incubated with purified a-syn (donor fraction) in presence or absence of a-syn-/- (KO) cytosol.\nResults are normalized to the maximal binding observed for each respective a-syn... (One-Way ANOVA: Wt: p < 0.0001, n = 4; A30P: p < 0.0001, n = 4; A53T p < 0.001, n = 4).",
          "judgment": "Yes",
          "reasoning": "The experiment included negative/null controls (synaptosomes from alpha-synuclein knockout mice). They also include experiments in the presence and absence of cytosol. The experiments were performed with multiple replicates (n=4).",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "KO synaptic membranes were incubated, for 10 min at 37°C, with 3 µg of Wt, A30P or A53T purified a-syn in absence or presence of 1.5 mg/ml of KO cytosol.  As shown on this graph, A30P purified a-syn has a lower binding compared to Wt and A53T a-syn in absence ...or presence ... of KO cytosol.",
          "judgment": "Yes",
          "reasoning": "They used wild-type a-syn as a comparator. While it's not a *known* benign, it functionally is intended to represent normal function. They also have A53T, which is a separate pathogenic variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "One-Way ANOVA: Wt: p < 0.0001, n = 4; A30P: p < 0.0001, n = 4; A53T p < 0.001, n = 4.",
          "judgment": "No",
          "reasoning": "The paper performed statistical analyses (ANOVA) and reports p-values, but does not provide the statistics to directly calculate an OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Variants tested were A30P, A53T (both PD-associated), and wild-type.",
          "judgment": "Yes",
          "reasoning": "Three variant 'controls' were used: A30P, A53T, and wild-type. Two are disease associated. This is greater than 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "A30P shows reduced membrane binding in vitro in the absence and presence of cytosol relative to wild type and A53T. There are appropriate controls and replicates in the experiment. Statistical analyses were conducted. Since there were more than 11 controls, the final score is PS3_moderate"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Alpha-Synuclein (a-syn), a 140 amino acid protein associated with presynaptic membranes in brain, is a major constituent of Lewy bodies in Parkinson's disease (PD). Three missense mutations (A30P, A53T and E46K) in the a-syn gene are associated with rare autosomal dominant forms of familial PD.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the misfolding and aggregation of alpha-synuclein, leading to Lewy body formation in Parkinson's disease. It is implied that the functional assay can show a difference in binding affinity between wild-type and mutant SNCA, which can affect protein accumulation and aggregation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In the present study, we analysed the ability of cytosolic factors to regulate a-syn binding to synaptic membranes... Our results revealed that ATP and lipids are two of the principal cytosolic components that modulate the a-syn binding.",
          "judgment": "Yes",
          "reasoning": "The assay class (binding assay) is applicable to the disease mechanism, as it directly probes the interaction of alpha-synuclein with membranes, which is relevant to its normal function and pathological aggregation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Figure 1A: Synaptosomes from a-syn-/- mice... incubated with purified a-syn (donor fraction) in presence or absence of a-syn-/- (KO) cytosol.\nResults are normalized to the maximal binding observed for each respective a-syn... (One-Way ANOVA: Wt: p < 0.0001, n = 4; A30P: p < 0.0001, n = 4; A53T p < 0.001, n = 4).",
          "judgment": "Yes",
          "reasoning": "The experiment included negative/null controls (synaptosomes from alpha-synuclein knockout mice). They also include experiments in the presence and absence of cytosol. The experiments were performed with multiple replicates (n=4).",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "KO synaptic membranes were incubated, for 10 min at 37°C, with 3 µg of Wt, A30P or A53T purified a-syn in absence or presence of 1.5 mg/ml of KO cytosol.  As shown on this graph, A30P purified a-syn has a lower binding compared to Wt and A53T a-syn in absence ...or presence ... of KO cytosol.",
          "judgment": "Yes",
          "reasoning": "They used wild-type a-syn as a comparator. While it's not a *known* benign, it functionally is intended to represent normal function. They also have A30P, which is a separate pathogenic variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "One-Way ANOVA: Wt: p < 0.0001, n = 4; A30P: p < 0.0001, n = 4; A53T p < 0.001, n = 4.",
          "judgment": "No",
          "reasoning": "The paper performed statistical analyses (ANOVA) and reports p-values, but does not provide the statistics to directly calculate an OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Variants tested were A30P, A53T (both PD-associated), and wild-type.",
          "judgment": "Yes",
          "reasoning": "Three variant 'controls' were used: A30P, A53T, and wild-type. Two are disease associated. This is greater than 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "A53T shows comparable or increased membrane binding in vitro compared to wild type in the absence of cytosol. In the presence of cytosol the binding affinity increases. There are appropriate controls and replicates in the experiment. Statistical analyses were conducted. Since there were more than 11 controls, the final score is PS3_moderate"
    }
  ]
}
